Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease

Gary W. Small1,2,3,4, Linda M. Ercoli2,4, Daniel Silverman2, S C Huang2, Scott Komo2,4, Susan Y. Bookheimer5,2,4, Helen Lavretsky2,4, Karen J. Miller2,4, Prabha Siddarth2,4, Natalie Rasgon2,4, John C. Mazziotta2, Sanjaya Saxena2, Hui‐Yuan Wu2, Michael S. Mega2, Jeffrey L. Cummings2,4, Ann M. Saunders2, Margaret A. Pericak‐Vance2, Tommy Martinsson2,4, Jorge R. Barrio2,4, Michael E. Phelps2
1Center on Aging and
2Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024; Departments of Molecular and Medical Pharmacology and Neurology, and Brain Mapping Center, University of California, Los Angeles, CA 90095; Department of Medicine, Duke University Medical Center, Durham, NC 27710; and Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
3Department of Medicine, Duke University Medical Center, Durham, NC 27710; and
4Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709
5Brain Mapping Center, University of California, Los Angeles, CA 90095;

Tóm tắt

The major known genetic risk for Alzheimer's disease (AD), apolipoprotein E-4 (APOE-4), is associated with lowered parietal, temporal, and posterior cingulate cerebral glucose metabolism in patients with a clinical diagnosis of AD. To determine cognitive and metabolic decline patterns according to genetic risk, we investigated cerebral metabolic rates by using positron emission tomography in middle-aged and older nondemented persons with normal memory performance. A single copy of the APOE-4 allele was associated with lowered inferior parietal, lateral temporal, and posterior cingulate metabolism, which predicted cognitive decline after 2 years of longitudinal follow-up. For the 20 nondemented subjects followed longitudinally, memory performance scores did not decline significantly, but cortical metabolic rates did. In APOE-4 carriers, a 4% left posterior cingulate metabolic decline was observed, and inferior parietal and lateral temporal regions demonstrated the greatest magnitude (5%) of metabolic decline after 2 years. These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(95)91556-7

10.2307/3350099

10.2105/AJPH.84.8.1261

10.1001/jama.1997.03550160083043

10.1007/BF00308809

10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X

10.1007/s004010050958

10.1007/s004010050595

10.1001/archneur.56.3.303

10.1080/87565648609540348

S L Rogers, L T Friedhoff Dementia 7, 293–303 (1996).

10.1001/jama.1995.03520360056039

10.1212/WNL.43.8.1467

10.1126/science.8346443

10.1038/ng0694-180

10.1002/ana.410400111

10.1038/jcbfm.1982.14

10.1126/science.2860723

10.1002/ana.410060502

S C Huang, M E Phelps, E J Hoffman, K Sideris, C J Selin, D E Kuhl Am J Physiol 238, E69–82 (1980).

10.1016/S1095-0397(99)00020-5

10.1056/NEJM199603213341202

10.1001/jama.1993.03500180078038

D A Wechsler Wechsler Memory Scale-Revised (Psychological Corp., New York, 1981).

10.1212/WNL.24.11.1019

A L Benton The Revised Visual Retention Test (Psychological Corp., New York, 1974).

10.1212/WNL.34.7.939

10.1001/archneur.1997.00550150035013

10.1097/00002093-199812000-00018

10.1109/23.340657

J Talairach, P Tournoux Coplanar Stereotaxic Atlas of the Human Brain. Three-Dimensional Proportional System: An Approach to Cerebral Imaging (Thieme, New York, 1988).

10.1038/jcbfm.1991.42

10.1002/hbm.460030303

10.1006/nimg.1996.0074

10.1016/S0016-5085(97)70220-8

10.1002/hbm.460020402

10.1097/00004647-199609000-00005

10.1007/s007020050097

10.1006/brcg.1996.0071

10.1001/jama.1997.03550150041033

J C Mazziotta, M E Phelps Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart, eds M Phelps, J Mazziotta, H Schelbert (Raven, New York), pp. 493–579 (1986).

10.1093/brain/122.8.1519

10.1016/0197-4580(93)90018-7

10.1212/WNL.49.3.786

10.1212/WNL.50.6.1585

10.1002/ana.410440226

10.1212/WNL.47.1.166

10.1016/S0149-2918(98)80145-8

10.1001/jama.1996.03540210033030